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BACKGROUND: Ovarian cancer shows considerable heterogeneity in its sensitivity to chemotherapy both clinically and in vitro.
This study tested the hypothesis that the molecular basis of this difference lies within the known resistance mechanisms inherent to
these patients’ tumours.
METHODS: The chemosensitivity of a series of 31 ovarian tumours, all previously treated with platinum-based chemotherapy, was
assessed using the ATP-based tumour chemosensitivity assay (ATP-TCA) and correlated with resistance gene expression measured
by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) in a TaqMan Array following extraction of mRNA from
formalin-fixed paraffin-embedded tissue. The results were standardised against a housekeeping gene (PBGD), and assessed by
multiple linear regression.
RESULTS: Predictive multiple linear regression models were derived for four single agents (cisplatin, gemcitabine, topotecan, and treosulfan),
and for the combinations of cisplatinþ gemcitabine and treosulfanþ gemcitabine. Particularly strong correlations were obtained for
cisplatin, gemcitabine, topotecan, and treosulfanþ gemcitabine. No individual gene expression showed direct correlation with activity in
the ATP-TCA. Genes involved in DNA repair and apoptosis were strongly represented, with some drug pumps also involved.
CONCLUSION: The chemosensitivity of ovarian cancer to drugs is related to the expression of genes involved in sensitivity and
resistance mechanisms.
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The variable response to chemotherapy in ovarian cancer is well
recognised clinically. Patients crossing from one regimen to the
alternative in clinical trials often show responses (Piccart et al,
2000; Muggia, 2003). This suggests that it might be possible to
optimise therapy if it was also possible to develop a test to
determine which regimen would be most effective for an individual
patient. We and others have used cellular chemosensitivity tests
to show similar heterogeneity in ovarian cancer, and clinical
comparisons suggest that these tests correlate relatively well with
outcome (Andreotti et al, 1995; Kurbacher et al, 1998; Konecny
et al, 2000; Sharma et al, 2003; Cree et al, 2007) despite the rapid
development of resistance in many patients (Di Nicolantonio et al,
2005). Clinical use of such tests is more problematic and requires
access to specialist laboratory facilities, as well as a large amount of
fresh tumour tissue. These assays have therefore failed to be widely
accepted into clinical practice.
Molecular assays offer the prospect of developing predictive
assays capable of wider use. However, studies of single genes have
shown little predictive efficacy, unless they happen to be the
targets of the drugs concerned. Multi-gene signatures are likely to
be required. There are two feasible approaches to the generation
of multi-gene signatures for predictive testing. The first is to
screen very large numbers of genes using hybridisation arrays,
correlate these with clinical outcome, and apply sophisticated
statistical methods to generate predictive gene signatures
(Wigle et al, 2002; Potti et al, 2006). The second is to take an
hypothesis-driven approach to generate gene sets based on
knowledge of the pathways involved in resistance and sensitivity
to individual drugs that can then be correlated with in vitro
chemosensitivity data or clinical outcome (Kikuchi et al, 2003). We
have taken the latter approach and have designed gene sets for
chemosensitivity prediction based on published reports and
previous studies.
In ovarian cancer, platinum (usually carboplatin) is the
mainstay of treatment in the primary setting, with single-agent
response rates around 60% (Lokich and Anderson, 1998). Single
agents such as paclitaxel, topotecan, and liposomal doxorubicin
are used as second-line treatments with response rates around
20% (Sharma et al, 2003). Other drugs such as alkylating agents
(e.g. treosulfan) also have activity and we have shown that the
combination of treosulfanþ gemcitabine is particularly active
(Cree, 2003; Sharma et al, 2003). Combination of gemcitabine
with platinum, even following previous treatment is effective due
to the ability of gemcitabine to reverse resistance associated with
enhanced DNA repair (Cree, 2003).
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The mechanisms of resistance to these agents have been studied
in some detail. Clinical studies using genome-wide gene expression
arrays have been performed and have shown signatures associated
with resistance to a number of agents (Richardson and Kaye, 2005;
Tsuda et al, 2005; Olivier et al, 2006). It is generally assumed that
the same resistance mechanisms used by cells to circumvent
single-agent activity will also be used against combinations of
these drugs. However, there are few mechanistic studies of
resistance to the combinations used in ovarian cancer to confirm
or refute this supposition.
This study has tested the hypothesis that the molecular basis of
the observed heterogeneity of chemosensitivity of ovarian cancer is
determined by the known resistance mechanisms expressed by these
patients’ tumours. Resistance to anti-cancer drugs involves many
mechanisms (Cree et al, 2002a, b), and an array-based approach to
study the genes involved is therefore sensible. The mechanisms
of cellular (i.e. non-pharmacokinetic) resistance to chemotherapy
include down-regulation of target expression, drug metabolism,
membrane-located xenobiotic pumps, altered susceptibility to
apoptosis, and altered growth/cell cycle or differentiation. Knowl-
edge of these pathways enabled us to design a TaqMan Array
microfluidic quantitative reverse-transcriptase PCR (qRT-PCR)
card to include 91 genes known to be involved in drug resistance/
sensitivity to anthracyclines, 5-FU, alkylating agents, and taxanes.
The card also included five housekeeping genes to allow standardi-
sation of the results for comparison of individual tumour data. The
gene set chosen was not intended to be comprehensive, but to
establish proof of principle for the use of in vitro sensitivity data
with gene expression data to determine the contribution of
individual genes to drug sensitivity and resistance in ovarian cancer.
PATIENTS AND METHODS
In this study we have used qRT-PCR to examine the expression of
genes previously shown to be involved in resistance to chemother-
apy with platinum, anthracyclines, taxanes, and alkylating agents
in ovarian cancer. The expression profiles have been compared
with quantitative chemosensitivity data obtained for the same
tumours using the ATP-based chemosensitivity assay tumour
chemosensitivity assay (ATP-TCA).
Patients and samples
A series of 31 ovarian tumour samples were obtained from surgical
specimens of platinum-pre-treated patients debulking surgery or at
staging laparoscopy with written consent from 2001 to 2006. Ethics
committee approval was obtained and the study conformed to the
Declaration of Helsinki Principles. The fresh samples were used to
obtain sensitivity data, and patients also had formalin-fixed
paraffin-embedded (FFPE) material taken for histology. This
provided a source of material for qRT-PCR. The age of patients
ranged from 18 to 57 years (average 38 years), and all were FIGO
stage 3c or IV. Histologically, 10 tumours were classified as papillary
serous, 4 as clear cell, 3 endometrioid, 1 mixed mullerian,
1 mucinous, and the remaining 12 as poorly differentiated by the
reporting pathologist. In 12 cases paclitaxel was given in addi-
tion to platinum as first-line treatment, 1 case received cisplatinþ
paclitaxel, and the remainder received carboplatin alone. Twelve
cases presented with early recurrence during or within 6 months of
initial treatment consistent with clinical resistance to platinum. Nine
patients were relapse cases following second-line treatment, whereas
the remainder were first relapse cases.
ATP-TCA
The ATP-TCA was performed as previously reported (Andreotti
et al, 1995; Cree, 1998). Samples from solid tumours were
transported to the laboratory in 25ml specimen bottles containing
cooled transport medium consisting of DMEM (Sigma, Poole,
Dorset, UK) with added antibiotics. Tumour cells were obtained by
enzymatic dissociation, washed in a serum-free complete assay
medium (CAM; available from DCS, Hamburg, Germany), and
purified by density centrifugation to remove debris. The cells were
washed, re-suspended in CAM, and plated in 96-well polypropylene
plates at 20 000 cells per well with six doubling dilutions of four
drugs or combinations, tested in triplicate from a 200% test drug
concentration (TDC) to 6.25% TDC. The concentrations of the drugs
used are given in Table 1. One row of each plate contained medium
only and one row a maximum inhibitor control. The plates were
incubated for 6 days at 371C with 5% CO2, following which ATP was
extracted with tumour cell extraction reagent (DCS). Aliquots of the
extract were transferred to a white 96-well polystyrene plate to which
an equal amount of luciferin-luciferase was added. The resulting
luminescence was read in a luminometer (MPLX; Berthold
Diagnostic Systems GmbH, Pforzheim, Germany) and the data were
transferred to an Excel (Microsoft) spreadsheet for analysis. The
results were expressed as the percentage inhibition at each
concentration tested compared with an untreated control, and
a summary index was calculated as the sum of the
surviving cell fraction at each concentration calculated as
600ÿSum(Inhibition600:Inhibition6.25) for comparison with qRT-
PCR results, where IndexSUM¼ 0 indicates complete inhibition and
IndexSUM¼ 600 indicates no effect (Hunter et al, 1993).
Extraction of mRNA from FFPE tumor tissue
The H&E-stained sections of selected FFPE blocks of ovarian
tumor tissue, previously marked with tumour areas of interest
(AOI) by a pathologist, were matched and overlaid onto the
corresponding FFPE block to give 480% neoplastic cells,
comparable with the ATP-TCA (Andreotti et al, 1995). The manual
tissue arrayer (MTA1; Beecher Instruments Inc., Sun Prairie, WI,
USA) fitted with a punch stylet 1.0mm in diameter was aligned
over the desired AOI, which was punched out from the block. The
stylet was decontaminated (Ambion DNA and RNA Zap) and
cleaned (70% alcohol) between each FFPE block. A minimum of
two 1.0mm punches were obtained from each block and placed in
a sterile labelled 1.5ml microcentrifuge tube.
The remainder of the extraction process was performed as
previously reported (Glaysher et al, 2009). In brief, the tubes were
heated at 701C in a Stuart SBH200D heating block (Bibby Scientific
Limited, Stone, Staffordshire, UK) for 20min. Excess paraffin wax
was subsequently removed and xylene was added to the tube for
10min at 501C. The microfuge tube was removed from the heating
block, centrifuged at 12 000 g for 2min in a Sanyo MSE Micro
Centaur centrifuge (MSE (UK) Ltd, Lower Sydenham, London,
Table 1 Drug list for ATP-TCA with manufacturer and 100% TDC used
in the assay and the number of tumours tested with each drug
Drug or
combination Manufacturer
100%
TDC (lM)
Number
tested
Cisplatin Bristol-Myers-Squibba 10.00 27
Doxorubicin Eli Lillyb 0.92 19
Gemcitabine Eli Lilly 40.04 26
Paclitaxel Bristol-Myers-Squibb 15.90 26
Topotecan GlaxoSmithKlinec 1.78 23
Treosulfan Medacd 71.86 23
Cisplatin+Gemcitabine As single agents As single agents 27
Treosulfan+Gemcitabine As single agents As single agents 26
Abbreviation: TDC¼ test drug concentration. Some samples had too few cells for all
single agents and combinations to be tested. aBristol-Myers Squibb Pharmaceuticals
Limited, Uxbridge, Middlesex, UK. bEli Lilly and Company Limited, Basingstoke,
Hampshire, UK. cGlaxoSmithKline plc, Brentford, Middlesex, UK. dmedac GmbH,
Hamburg, Germany.
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UK) and waste xylene was removed. The samples were washed two
additional times with xylene. Residual xylene was removed with
100% ethanol and the tubes were allowed to stand for 10min at
room temperature. Following centrifugation at 12 000 g for 5min,
the ethanol was removed by pipette, and the process was repeated
once more. The microfuge tube lids were opened to allow
evaporation of any residual ethanol at 501C for 10min, before
protease digestion.
Protease digestion and RNA extraction were performed using
an Ambion RecoverAll kit (catalogue no. AM1975; Applied
Biosystems, Life Technologies, Carlsbad, CA, USA.) according to
the manufacturer’s instructions as previously described (Glaysher
et al, 2009). The lysates resulting from protease digestion were stored
at ÿ201C before RNA extraction.
Two-step RT–PCR
Reverse transcription (RT) was performed using an High-Capacity
cDNA Archive Kit (catalogue no. 4322171; Applied Biosystems)
according to the manufacturer’s instructions and as previously
reported (Glaysher et al, 2009) in a 0.2ml PCR tube. The final RNA
concentration in the RT mix was 1–20 ngmlÿ1. Cycling conditions
were step 1, 251C for 10min, step 2, 371C for 120min. After
removal from the thermal cycler, the tubes were pulse spun in a
microfuge at 12 000 g for 30 s and stored overnight at 41C. The
following day cDNA content was measured using a NanoDrop
spectrophotometer before use in the TaqMan Array.
TaqMan Arrays (Applied Biosystems) were run according to the
manufacturer’s instructions (Glaysher et al, 2009). Samples were
made up with TaqMan  2 Universal Master Mix with UNG
Amperase (catalogue no. 4364338; Applied Biosystems) and mixed
with an equal volume of cDNA to give a final concentration of
300 ng mlÿ1 DNA. All four samples were then each pipetted into
two ports (100ml per port) of the 384-well card, for the 96 genes
arrayed in a Chemosensitivity Gene Expression Array (CGEA-1;
CanTech Ltd., Portsmouth, UK). The genes on each card are given
in Table 2. The loaded card was then placed, port upwards, into a
balanced centrifuge (type, address) and spun for 60 s at 380 g to fill
the card. This was checked and the card was spun again for 60 s at
380 g to remove any air bubbles. The card was then placed in a
TaqMan Array slide sealer for sealing, and the loading ports were
cut from the card before it was read in an 7900HT thermal cycler,
Applied Biosystems. PCR was performed for 90min with the
following conditions: AmpErase UNG Activation for 2min at 501C;
AmpliTaq Gold DNA Polymerase Activation for 10min at 94.51C;
followed by 40 cycles each of Melt Anneal/Extend for 30 s at 971C
and 1min at 59.71C. The ‘Auto Threshold Cycle’ function was
performed at the end of the run and Ct data were transferred to a
Microsoft Excel spreadsheet, controls were checked, and the data
were transferred to a Microsoft Access database for further
analysis.
Ct values were standardised against HMBS (PBGD), the least
variable housekeeping gene, to avoid errors due to differences
in efficiency between the housekeeping and test genes, which
were present from cycle 27 to 35 in most cases. A logarithmic
gene expression ratio was calculated as Ln(2ÿCt(test)/2ÿCt(PBGD))
and used for comparison with ATP-TCA data by multiple linear
regression using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA)
and Analyse-It software (Analyse-it Software Ltd, Leeds, UK)
applications.
Data analysis
The ATP-TCA and qRT-PCR data were collected into an Access
database (Microsoft), from which descriptive statistics were
generated. Comparison of ATP-TCA results for individual drugs
or combinations with gene expression data was performed by
multiple linear regression with forward selection of variables using
SPSS version 15.0. For each variable, inclusion was dependant
upon a probability of F40.1, that is, the threshold for inclusion of
a gene into the model within SPSS, based on initial assessment of
the most appropriate model size using Akaike Information
Criterion, a function of model error and size that penalises large
models (data not shown). The prediction residual sum of squares
method was used as this is an adjusted regression method helpful
in preventing overfitting of the data as it uses a ‘leave one out’
method of analysis. Genes were added by forward regression
according to their univariate correlations following entry of each
gene into the model, and no intercept term was included.
RESULTS
ATP-TCA
In keeping with previous results from a number of articles
(Andreotti et al, 1995; Sharma et al, 2003), the results from
the ATP-TCA show considerable heterogeneity for each of
the drugs and combinations tested. The frequency histograms
show the greatest activity (i.e. lowest IndexSUM) for treosul-
fanþ gemcitabine, whereas the single agents showed weaker but
more variable activity (Figure 1).
qRT-PCR
Although these qRT-PCR studies were performed using RNA
extracted from FFPE tissue, all samples were regarded as evaluable
on the basis of the housekeeping gene Ct levels (i.e. HMBS/PBGD
Ct437 cycles). Variation in housekeeping gene levels was limited,
with a normal distribution of Ct levels (HMBS/PBGD, mean¼
31.61, 95% CI¼ 30.43–32.78). Ct levels within the detectable range
were present for most of the genes present on the TLDA, though
Table 2 Genes present on the TaqMan Array with their likely
contribution to drug resistance mechanisms
Apoptosis Pumps/Detox DNA repair Proliferation
AKT ATP7B ATM APC C-term
APAF1 BCRP BRCA1 APC N-term
BAD CES1 ERCC1 b-TUBULIN III
BAX CES2 ERCC2 COX2
BCL2 cN II GTF2H2 EGFR
BCL-x(L) DPD MGMT HER2
BID FPGS MLH1 HER3
c-FLIP gH2AX MSH2 HER4
FAS GCLC MSH6 HIF1A
FASL GCLM RAD51 KI67
HSP60 GSTp TOPO I P16
HSP70 hENT1 TOPO IIa P21
HSP90 hENT2 TOPO IIb P27
IAP2 MDR1 XPA P53
IGF1 MRP1 XRCC1 VEGF
IGF1R MRP2 XRCC5
IGF2 MRP3 XRCC6
IGF2R MRP4
IGFBP1 MRP5
IGFBP2 MRP6
MCJ MRP8
MCL1 MTII
mTOR MVP
NFkB OPRT
PIK3CA RRM1 Housekeeping genes
PTEN SOD1 18S
STAT3 TAP1 HPRT
SURVIVIN TAP2 PBGD
XIAP TAP4 SDHA
TS TBP
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some were more rarely expressed than others. NTC remained
undetectable throughout the study indicating that the reagents and
cards in use had not been contaminated. Control data showed
an intra-assay coefficient of variation (CoV) for one sample of
0.69% for PBGD/HMBS. The inter-assay variation for PBGD/HMBS
with six samples varied between 1 and 3%.
Correlation of mechanisms with ATP-TCA data
Drugs susceptible to particular resistance mechanisms showed
good correlation with genes linked to these mechanisms (Figure 2),
provided that the drugs were sufficiently active and showed
heterogeneity of chemosensitivity, though doxorubicin and
paclitaxel were less highly correlated with gene expression in
comparison with other drugs or combinations in multiple linear
regression analyses. All of the genes on the TaqMan Arrays were
previously related to drug resistance or sensitivity, and this cannot
therefore be regarded as a naive data set, but for the purpose of
this report the SPSS analysis included all genes present on the card.
The genes involved in each of the forward multiple regression
models identified and the coefficients for each are shown in
Table 3 in the order of greatest contribution to the model.
Although the number of tumours is relatively small for each
model, the results are impressive. The cisplatin and treosulfan
models contain a number of DNA repair genes and others
associated with apoptosis pathways, consistent with the known
resistance mechanisms for DNA-damaging agents. The topotecan
model includes a drug pump, including MRP4, and several of the
models include p21 or p53. Weaker correlations were noted for
doxorubicin and paclitaxel, perhaps suggesting that genes that
were not represented on the array may be involved in ovarian
cancer sensitivity and resistance to these drugs.
The combination of cisplatin with gemcitabine was influenced
by the presence of one highly resistant tumour, and by the limited
variation between the remainder of the results. However, this did
not appear to be a problem for the treosulfan with gemcitabine
model, which achieved a high degree of correlation despite the
presence of a very resistant tumour.
DISCUSSION
In this study we have examined single-agent and combination
effects for the same tumours using the ATP-TCA, and compared
this experimental in vitro chemosensitivity data with the expres-
sion of a large number of potential resistance mechanisms using
qRT-PCR to study FFPE biopsy material. The TaqMan Array assay
can be performed with a few nanograms of RNA extracted from
FFPE blocks stored in pathology, and this gives it a considerable
advantage over the ATP-TCA that requires large amounts of fresh
tissue. Most of the samples used in this study were from surgical
material, but in each case we have used just two 1.0mm punches
from the FFPE blocks. The ability to use small punches of tumour
identified by the pathologist in paraffin blocks makes this a
potentially very valuable technique, as it is also be possible to
measure gene amplification or mutation by PCR of DNA markers.
If gene expression for sensitivity and resistance genes proves also
to be related to clinical outcome, it should be feasible to develop
arrays using smaller numbers of gene that can predict the efficacy
of chemotherapy regimens for individual patients and to optimise
patient treatment on this basis. However, it should be noted that
the gene signatures identified in this study are models for acquired
resistance from a very mixed poor prognosis group of patients
with ovarian cancer and unlikely to be applicable to a first-line
therapy setting.
Unlike direct correlation of gene expression with clinical data,
the comparison of quantitative gene expression data (CoV 2%)
with in vitro chemosensitivity data from the ATP-TCA (CoV 15%)
means that relatively small numbers of tumours are required to
obtain data on the genes relevant to resistance and sensitivity to
drugs tested in the assay. This may prove to be particularly useful
to investigate the mechanisms of sensitivity and resistance for
drugs that are rarely used as single agents, and to develop
predictive molecular assays for new drugs about to enter the
clinical use. It is undoubtedly true that our array does not include
all the genes of relevance to the drugs tested – the lack of good
correlation with some agents may reflect this, or general resistance
that would result in poorer correlation due to a lack of
heterogeneity. However, much of the previous work on the
influence of gene expression on chemosensitivity has been carried
out in cell lines, which show differences in their chemosensitivity
to tumour-derived cells tested in xenografts (Fiebig et al, 2004) or
primary cultures (Fernando et al, 2006). Because the array was
manufactured, several new correlations of gene expression with
drugs active in ovarian cancer have since been described, for
example gemcitabine in which ribonucleotide reductase subunits
may be involved (Smid et al, 2006), and paclitaxel in which YY1
expression has been implicated (Matsumura et al, 2009). Further
work is therefore required to define gene sets that might be
clinically useful.
The genes identified are involved in several known mechanisms
of chemoresistance, including drug metabolism, membrane drug
pumps, and DNA repair. These are relatively specific to particular
drugs, but in nearly all of the models generated, expression of
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Figure 1 Box and whisker plot showing the sensitivity of tumours to each drug tested. IndexSUM is higher in resistance, lower in sensitive tumours.
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Figure 2 Multiple linear regression analysis by unsupervised forward selection for (A) cisplatin ÿ Adj R2¼ 0.836, Po0.001; (B) doxorubicin ÿ Adj
R2¼ 0.524, Po0.007; (C) gemcitabine ÿ Adj R2¼ 0.524, Po0.001; (D) paclitaxel ÿ Adj R2¼ 0.646, Po0.001; (E) topotecan ÿ Adj R2¼ 0.751, Po0.001;
(F) treosulfan ÿ Adj R2¼ 0.977, Po0.001; (G) cisplatinþ gemcitabine ÿ Adj R2¼ 0.743, Po0.001; (H) treosulfanþ gemcitabine ÿ Adj R2¼ 0.753,
Po0.001.
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genes involved in apoptosis proved to be important, suggesting
that the general susceptibility of the cell to undergo apoptosis may
outweigh other determinants of tumour chemosensitivity (Cree
et al, 2002a; Glaysher et al, 2009). In general, the genes we have
found to be important match well with those thought to be
important from previous studies. There are some discrepancies,
for instance in which membrane pumps are involved in doxo-
rubicin or topotecan resistance. Such instances may be explained
by covariance, as several such pumps tend to be up-regulated
together following exposure of ovarian cancer cells to pumped
drugs (Di Nicolantonio et al, 2005). The number of tumours in this
study is relatively small, and it is important not to draw too much
from these data – the likelihood of the signatures described here
being optimal for prediction of chemosensitivity is remote, and
much larger studies using clinical samples will be required to
validate signatures for clinical use. It is however conceivable
that gene signatures may be similar for patients with resistance to
particular agents. Sub-clustering of groups with distinct mech-
anisms of resistance is conceivable in bigger studies, and could
allow stratification of patients in clinical trials.
CONCLUSION
This study supports the hypothesis that the molecular basis of the
observed difference in sensitivity between ovarian tumours lies
within the known resistance mechanisms inherent to these
patients’ tumours, as we have described in lung cancer (Glaysher
et al, 2009). The TaqMan Array is well suited to investigate the
presence of these mechanisms in ovarian cancers alongside cellular
chemosensitivity testing and clinical results, and its ability to use
small fragments of tumour tissue makes it suited to development
for future clinical use.
Table 3 Genes found to correlate in multivariate linear regression
analysis
Model R R2 Adj R2
Std.
error
Significance
(ANOVA)
(A)
Cisplatin 0.949 0.901 0.836 35.226 Po0.001
Doxorubicin 0.797 0.636 0.524 98.669 Po0.007
Gemcitabine 0.766 0.586 0.524 88.312 Po0.001
Paclitaxel 0.848 0.720 0.646 78.669 Po0.001
Topotecan 0.900 0.811 0.751 60.457 Po0.001
Treosulfan 0.994 0.989 0.977 10.769 Po0.001
Cisplatin+Gemcitabine 0.899 0.807 0.743 63.769 Po0.001
Treosulfan+Gemcitabine 0.904 0.817 0.753 33.823 Po0.001
Unstandar-
dized
Collinearity
statistics
Gene
B
Std.
Error
Standar-
dized
b
t
Lower
bound B
Std.
error
(B)
Cisplatin
(Constant) 489.826 22.739 21.541
Rad51 ÿ41.140 6.003 ÿ0.801 ÿ6.853 0.482 2.077
IGF1R ÿ61.361 11.034 ÿ0.737 ÿ5.561 0.375 2.668
p53 19.690 8.267 0.217 2.382 0.792 1.263
Topo I 43.796 9.300 0.522 4.709 0.534 1.872
MRP5 17.255 5.629 0.345 3.065 0.518 1.929
Survivin ÿ11.745 4.880 ÿ0.286 ÿ2.407 0.466 2.145
HSP60 42.165 9.610 0.491 4.388 0.526 1.901
BCRP ÿ21.628 5.093 ÿ0.632 ÿ4.247 0.297 3.368
Mcl-1 16.918 6.486 0.252 2.609 0.707 1.414
Ki67 11.667 5.487 0.259 2.126 0.442 2.264
Doxorubicin
(Constant) 69.454 125.422 0.554
GST pi 106.938 31.844 0.649 3.358 0.751 1.332
MRP4 80.498 25.470 0.585 3.161 0.817 1.225
MRP5 ÿ36.958 13.921 ÿ0.500 ÿ2.655 0.790 1.266
Topo IIa ÿ14.009 16.405 ÿ0.164 ÿ0.854 0.759 1.318
Gemcitabine
(Constant) 407.883 28.640 14.242
(Constant) 454.312 37.512 12.111
MCJ ÿ46.173 10.778 ÿ0.621 ÿ4.284 0.983 1.018
XRCC1 52.043 14.788 0.571 3.519 0.785 1.274
XPA ÿ48.982 19.639 ÿ0.402 ÿ2.494 0.797 1.255
Paclitaxel
(Constant) 343.514 37.244 9.223
Survivin ÿ42.179 8.466 ÿ0.675 ÿ4.982 0.804 1.245
IGF2R 109.226 18.578 1.122 5.879 0.405 2.472
Mcl-1 ÿ70.805 17.654 ÿ0.799 ÿ4.011 0.372 2.689
GCLM 40.381 12.968 0.490 3.114 0.596 1.677
TAP2 ÿ36.754 15.467 ÿ0.333 ÿ2.376 0.750 1.333
Topotecan
(Constant) 356.986 30.510 11.701
APAF1 75.074 11.458 0.805 6.552 0.785 1.274
SDHA ÿ42.701 9.085 ÿ0.578 ÿ4.700 0.783 1.277
HER2 ÿ41.223 8.955 ÿ0.618 ÿ4.604 0.657 1.521
MRP4 55.124 15.928 0.510 3.461 0.546 1.831
IGF2R 36.298 15.445 0.355 2.350 0.520 1.924
Treosulfan
(Constant) ÿ46.200 22.925 ÿ2.015
MLH1 42.868 1.922 0.893 22.304 0.646 1.549
Bax 75.608 5.919 0.927 12.774 0.197 5.083
Bcl2 ÿ31.437 1.650 ÿ1.244 ÿ19.054 0.243 4.115
p21 ÿ69.282 3.493 ÿ1.218 ÿ19.837 0.275 3.641
GST pi 106.821 6.921 1.176 15.433 0.178 5.608
Ki67 ÿ17.337 1.649 ÿ0.509 ÿ10.511 0.441 2.266
APC N-term 56.943 5.738 0.870 9.924 0.135 7.417
(B)
HIF1A ÿ45.059 6.890 ÿ0.566 ÿ6.539 0.138 7.224
p16 7.875 1.539 0.208 5.117 0.629 1.589
Survivin ÿ7.258 1.554 ÿ0.223 ÿ4.671 0.455 2.198
Bid ÿ15.379 4.423 ÿ0.204 ÿ3.477 0.301 3.327
Cisplatin+Gemcitabine
(Constant) ÿ195.787 106.134 ÿ1.845
FPGS 58.087 11.147 0.630 5.211 0.733 1.364
IGFBP2 ÿ27.128 11.555 ÿ0.275 ÿ2.348 0.778 1.285
MDR1 ÿ52.072 8.573 ÿ0.871 ÿ6.074 0.520 1.922
18s 48.716 11.831 0.578 4.118 0.543 1.841
XRCC5 144.209 32.907 0.859 4.382 0.278 3.591
HIF1A ÿ76.886 25.948 ÿ0.555 ÿ2.963 0.305 3.281
Treosulfan+gemcitabine
(Constant) 280.890 22.522 12.472
ATP7B ÿ25.392 4.143 ÿ0.721 ÿ6.128 0.776 1.289
Bad 27.786 8.089 0.401 3.435 0.787 1.271
MTII ÿ55.067 10.870 ÿ0.648 ÿ5.066 0.657 1.521
p53 34.839 8.973 0.485 3.883 0.690 1.449
IGF2 ÿ12.457 3.713 ÿ0.391 ÿ3.355 0.791 1.265
GCLM 11.706 4.972 0.272 2.354 0.807 1.239
Abbreviation: ANOVA¼ analysis of variance. (A) With ATP-TCA data for recurrent
ovarian cancer: model summaries; (B) using forward selection: coefficients for each
gene included in the model by drug or combination tested.
Table 3 Continued
Unstandar-
dized
t
Collinearity
statistics
Gene B
Std.
Error
Standar-
dized
b
Lower
bound B
Std.
error
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